As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 29, 2012
by Ken Grogan for Pharma Times:
Lundbeck says its investigational Alzheimer’s disease drug Lu AE58054 has met its primary endpoint in a mid-stage study.
The Phase II trial was conducted in 278 patients suffering from moderate Alzheimer’s and Lu AE58054 was administered as add-on to Eisai/Pfizer’s blockbuster dementia drug Aricept (donepezil). The Danish drugmaker’s treatment plus donepezil demonstrated significant improvements in cognitive function in Alzheimer’s disease compared to placebo plus donepezil.
Lundbeck noted that secondary endpoints, including measures of global status and activities of daily living also showed positive trends with the addition of Lu AE58054, compared with patients who only received Aricept. The new drug was also considered to be well tolerated at the selected dose.
Head of R&D, Anders Gersel Pedersen, said the results are very encouraging “and we are now evaluating how to best proceed with the development of Lu AE58054”. The firm is looking at a major pivotal clinical programme “potentially including development and commercial partnerships”.
Lu AE58054 is a novel, selective 5HT6 receptor antagonist with a different mechanism of action than currently-available Alzheimer’s medications.
Source: http://www.pharmatimes.com/Article/12-05-29/Lundbeck_Alzheimer_s_drug_impresses_in_Phase_II.aspx
Picture Source: WebMD
A new comprehensive study from Florida State University (FSU) finds no evidence to support the idea that personality changes begin before the clinical onset of mild cognitive impairment (MCI) or dementia. MCI is an intermediate...
On the evening of Monday November 27th, join us for conversation and cocktails with award-winning journalist, editor and author Tina Brown, and Indigo’s CEO Heather Reisman. Hear from Tina Brown about her eight-year tenure at Vanity...
The presence of TAR DNA-binding protein 43 (TDP-43) in the hippocampus on postmortem examination is associated with increased rates of hippocampal atrophy in patients with Alzheimer’s disease (AD), new research suggests. This association was greatest...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.
